Since 2016, the World Health Organization (WHO) has introduced molecular markers in its classification of central nervous system (CNS) tumors, allowing IDH‐mutant gliomas to be defined by their molecular features resulting in a more accurate diagnosis [8, 9]. Here, IDH2 is linked to central nervous system cancer.